VVP
MRNA icon

Venture Visionary Partners’s Moderna MRNA Stock Holding History

Venture Visionary Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,649
Closed -$1.17M – 534
2023
Q2 		$1.17M Sell
9,649
-27
-0.3% -$3.6K 0.07% 222
2023
Q1 		$1.49M Sell
9,676
-815
-8% -$134K 0.09% 185
2022
Q4 		$1.88M Sell
10,491
-460
-4% -$75.2K 0.14% 139
2022
Q3 		$1.29M Buy
10,951
+4,475
+69% +$679K 0.11% 164
2022
Q2 		$925K Buy
6,476
+4,635
+252% +$663K 0.07% 214
2022
Q1 		$317K Buy
1,841
+125
+7% +$21K 0.02% 402
2021
Q4 		$435K Sell
1,716
-134
-7% -$39.2K 0.03% 348
2021
Q3 		$711K Sell
1,850
-1,279
-41% -$472K 0.05% 261
2021
Q2 		$735K Buy
3,129
+485
+18% +$86.7K 0.06% 245
2021
Q1 		$346K Buy
+2,644
New +$383K 0.03% 350

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Venture Visionary Partners's MRNA Position: Q3 2023 in Review

Venture Visionary Partners sold out of Moderna (MRNA) in Q3 2023, closing a stake of 9,649 shares — an estimated $1.17M sold.

Venture Visionary Partners first reported a position in MRNA in Q1 2021 and held it in 10 quarters. The position peaked at $1.88M in Q4 2022. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Venture Visionary Partners reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Venture Visionary Partners sold 9,649 Moderna shares in Q3 2023, an estimated $1.17M.
  • Venture Visionary Partners first reported a position in Moderna in Q1 2021 and held it in 10 quarters.
  • Venture Visionary Partners's Moderna position peaked at $1.88M in Q4 2022.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Venture Visionary Partners's 13F filing for Q3 2023, filed 13 Oct 2023.